Israel Englander Cassava Sciences Inc Transaction History

Millennium Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.64 - $30.11 $727,710 - $1.73 Million	57,572 Added 618.19%	66,885 $1.51 Million
Q2 2023 Aug 14, 2023	SELL	$21.59 - $27.88 $966,778 - $1.25 Million	-44,779 Reduced 82.78%	9,313 $228,000
Q1 2023 May 15, 2023	BUY	$23.46 - $36.44 $778,637 - $1.21 Million	33,190 Added 158.79%	54,092 $1.31 Million
Q4 2022 Feb 14, 2023	BUY	$27.82 - $44.16 $329,694 - $523,340	11,851 Added 130.94%	20,902 $617,000
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $147,802 - $462,144	9,051 New	9,051 $379,000
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $4.3 Million - $10.6 Million	-116,851 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $3.05 Million - $9.87 Million	72,936 Added 166.08%	116,851 $7.25 Million
Q2 2021 Aug 16, 2021	SELL	$32.15 - $89.72 $5.95 Million - $16.6 Million	-185,061 Reduced 80.82%	43,915 $3.75 Million
Q1 2021 May 17, 2021	BUY	$7.09 - $87.95 $1.62 Million - $20.1 Million	228,976 New	228,976 $10.3 Million
Q2 2020 Aug 14, 2020	SELL	$2.04 - $9.64 $521,424 - $2.46 Million	-255,600 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$3.26 - $9.65 $746,152 - $2.21 Million	228,881 Added 856.62%	255,600 $1.05 Million
Q4 2019 Feb 14, 2020	BUY	$1.1 - $6.12 $29,390 - $163,520	26,719 New	26,719 $139,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $110M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.